logo
The Best High-Yield Midstream Stock to Invest $1,000 in Right Now

The Best High-Yield Midstream Stock to Invest $1,000 in Right Now

Yahoo12-07-2025
The midstream segment of the energy sector is known for its financial consistency.
One of the most consistent midstream businesses you can buy is Enterprise Products Partners.
Enterprise provides income investors with a powerful combination of distribution growth and yield.
10 stocks we like better than Enterprise Products Partners ›
Energy prices have been volatile recently due to geopolitical issues. And, in fact, oil prices have moved in ways that some onlookers hadn't been expecting, highlighting the inherent risks of investing in the energy sector. Unless, that is, you sidestep the commodity risk by focusing on the midstream. And there's one high-yield midstream option that stands out today.
Upstream energy businesses extract crude oil and natural gas. As such, their top and bottom lines are almost entirely dependent on commodity prices. Downstream businesses use oil and natural gas to produce chemicals and refined products such as gasoline. So not only do they rely on volatile-priced commodity inputs for their processes, but the products that they produce are largely commodities themselves.
Midstream energy businesses are different. They own energy infrastructure, like pipelines and storage facilities, that connects the upstream players to the downstream and on to the rest of the world. Midstream companies generally charge fees for the use of their assets, a business model that tends to generate consistent cash flows regardless of the prices of the commodities flowing through their systems. They use large fractions of those cash flows to pay dividends, which tend to be fairly generous in the midstream sector.
But not all midstream businesses are created equal. For example, at their current stock prices, Energy Transfer (NYSE: ET) is offering a 7.2% distribution yield while Enterprise Products Partners' (NYSE: EPD) yield is 6.9%. Yet if you are a dividend investor trying to build a reliable income stream for the long term, you'll be better off going with Enterprise's lower yield, whether you have $1,000 or $10,000 to invest.
Why not pick the stock with the highest yield? The answer is simple: Because consistency is more important to most long-term dividend investors than yield. That's especially true in a case like this one, where the difference between the two yields is only 30 basis points. The chart below clearly illustrates this.
Though the two have similar businesses, they don't always behave in the same way. Energy Transfer cut its dividend in 2020 amid the energy downturn caused by the start of the coronavirus pandemic. Sure, it returned to growing its payouts again fairly quickly, but those payments shrank dramatically right when most income seekers would have wanted reliability. By contrast, Enterprise Products Partners increased its distribution in 2020. Its streak of annual increases is now up to 26 consecutive years.
Boring and reliable distribution growth is a key reason why investors should be considering Enterprise Products Partners today. The high yield should be appealing, too. But there's another little wrinkle: The dividend isn't the only reliable and boring part of the business. The master limited partnership has a solid financial foundation (its balance sheet is investment-grade rated), and management sets realistic goals that it tends to hit year in and year out.
To use Energy Transfer as an example again, that business set plans in motion to buy another company in late 2015. An energy downturn in 2016, however, led Energy Transfer to get cold feet. It eventually scuttled the deal, but not without an ugly black eye from the legal battle that ensued. Or, consider Kinder Morgan (NYSE: KMI), another North American midstream giant. Its management team told investors to expect large dividend hikes in 2016 and 2020. Instead, in response to shifting macroeconomic conditions, it cut its payout in 2016 and provided a hike that fell well short of its original dividend goal in 2020.
Enterprise muddled through both of those tough periods for the energy sector in relative stride without making promises it couldn't keep or cutting its distributions.
Some investors might find reasons to justify buying Energy Transfer or Kinder Morgan over Enterprise Products Partners. But if you are putting $1,000 or more on the line, boring and reliable Enterprise provides a history of income and reliability that many of its peers just can't match. Erring on the side of safety is the right call in the energy sector, particularly if you're using the income your portfolio generates to help cover your living expenses.
Focusing on the midstream segment is a good first step. But homing in on an industry leader like Enterprise is even better. At the current stock price, a $1,000 investment would net you around 31 units of this reliable high-yield MLP.
Before you buy stock in Enterprise Products Partners, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Enterprise Products Partners wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,432!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,854!*
Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of July 7, 2025
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kinder Morgan. The Motley Fool recommends Enterprise Products Partners. The Motley Fool has a disclosure policy.
The Best High-Yield Midstream Stock to Invest $1,000 in Right Now was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share
XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share

Yahoo

time10 minutes ago

  • Yahoo

XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share

CHICAGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- XAI Madison Equity Premium Income Fund (the 'Fund'), has declared its regular monthly distribution of $0.060 per share on the Fund's common shares (NYSE: MCN) payable on September 2, 2025. The amount represents no change from the previous month's distribution amount. As mentioned in previous distribution declarations, the Fund has changed its distribution frequency from quarterly to monthly, which went into effect with the April 1, 2025 declaration. XA Investments believes this change enables investors to better manage their cash flow needs. Ex-Dividend Date August 15, 2025 Record Date August 15, 2025 Payable Date September 2, 2025 Amount $0.060 per share Change from Previous Month No Change The following dates apply to the declaration: Common share distributions may be paid from net investment income (regular interest and dividends), capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Fund's common shareholders on Form 1099 after the end of the 2025 calendar year. Shareholders should not assume that the source of a distribution from the Fund is net income or profit. For further information regarding the Fund's distributions, please visit . The Fund's net investment income and capital gain can vary significantly over time; however, the Fund seeks to maintain more stable common share quarterly distributions over time. The Fund's final taxable income for the current fiscal year will not be known until the Fund's tax returns are filed. As a registered investment company, the Fund is subject to a 4% excise tax that is imposed if the Fund does not distribute to common shareholders by the end of any calendar year at least the sum of (i) 98% of its ordinary income (not taking into account any capital gain or loss) for the calendar year and (ii) 98.2% of its capital gain in excess of its capital loss (adjusted for certain ordinary losses) for a one-year period generally ending on December 31 of the calendar year (unless an election is made to use the Fund's fiscal year). In certain circumstances, the Fund may elect to retain income or capital gain to the extent that the Board of Trustees, in consultation with Fund management, determines it to be in the interest of shareholders to do so. The common share distributions paid by the Fund for any particular period may be more than the amount of net investment income from that period. As a result, all or a portion of a distribution may be a return of capital, which is in effect a partial return of the amount a common shareholder invested in the Fund, up to the amount of the common shareholder's tax basis in their common shares, which would reduce such tax basis. Although a return of capital may not be taxable, it will generally increase the common shareholder's potential gain, or reduce the common shareholder's potential loss, on any subsequent sale or other disposition of common shares. Future common share distributions will be made if and when declared by the Fund's Board of Trustees, after the evaluation of several factors, including the Fund's net investment income, financial performance and available cash. There can be no assurance that the amount or timing of common share distributions in the future will be equal or similar to that described herein or that the Board of Trustees will not decide to suspend or discontinue the payment of common share distributions in the future. The Fund's objective is to achieve a high level of current income and current capital gains, with long-term capital appreciation as a secondary objective. The Fund intends to pursue its objective by investing in a portfolio of common stocks and utilizing an option strategy, primarily by writing (selling) covered call options on a substantial portion of the common stocks in the portfolio in order to generate current income and gains from option writing premiums and, to a lesser extent, from dividends. Market action can impact dividend issuance as the Fund's total assets affect the Fund's future dividend prospects. The Fund provides additional information on its website at . About XA Investments XA Investments LLC ('XAI') serves as the Fund's investment adviser. XAI is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund. The listed closed-end funds, the XAI Octagon Floating Rate & Alternative Income Trust and XAI Madison Equity Premium Income Fund both trade on the New York Stock Exchange and the interval fund, Octagon XAI CLO Income Fund is available via direct subscription and through select broker/dealers and wealth management platforms. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including development and market research, sales, marketing, and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. XAI provides individual investors with access to institutional-caliber alternative managers. For more information, please visit . About XMS Capital Partners XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit . About Madison Investments Madison Investments is an independent investment management firm based in Madison, WI. The firm was founded in 1974, has approximately $28.3 billion in assets under management as of March 31, 2025, and is recognized as one of the nation's top investment firms. Madison offers domestic fixed income, U.S. and international equity, covered call, multi-asset, insurance and credit union investment management strategies. For more information, please visit .Madison and/or Madison Investments is the unifying tradename of Madison Investment Holdings, Inc., Madison Asset Management, LLC, and Madison Investment Advisors, LLC. Madison Funds are distributed by MFD Distributor, LLC. Madison is registered as an investment adviser with the U.S. Securities and Exchange Commission. MFD Distributor, LLC is registered with the U.S. Securities and Exchange Commission as a broker-dealer and is a member firm of the Financial Industry Regulatory Authority . XAI does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax. Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Fund carefully before investing. For more information on the Fund, please visit the Fund's webpage at . This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE Media Contact:Kimberly Flynn, PresidentXA Investments LLCPhone: 888-903-3358Email: KFlynn@ in to access your portfolio

US securities regulator announces AI task force
US securities regulator announces AI task force

Yahoo

time10 minutes ago

  • Yahoo

US securities regulator announces AI task force

(Reuters) -The U.S. Securities and Exchange Commission said on Friday that it is creating an artificial intelligence task force to lead the agency's efforts to "enhance innovation and efficiency" in its operations. Valerie Szczepanik, who has been named the SEC's chief AI officer, will lead the task force, the regulator said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Yahoo

time10 minutes ago

  • Yahoo

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store